ZA200409430B - Process for the manufacture of quinoline derivatives. - Google Patents
Process for the manufacture of quinoline derivatives.Info
- Publication number
- ZA200409430B ZA200409430B ZA200409430A ZA200409430A ZA200409430B ZA 200409430 B ZA200409430 B ZA 200409430B ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 B ZA200409430 B ZA 200409430B
- Authority
- ZA
- South Africa
- Prior art keywords
- manufacture
- quinoline derivatives
- formula
- quinoline
- chaineded
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201778A SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Process for the manufacture of quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200409430B true ZA200409430B (en) | 2006-02-22 |
Family
ID=20288148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200409430A ZA200409430B (en) | 2002-06-12 | 2004-11-23 | Process for the manufacture of quinoline derivatives. |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1511732B9 (pt) |
JP (1) | JP4584709B2 (pt) |
KR (1) | KR100979216B1 (pt) |
CN (1) | CN100418950C (pt) |
AT (1) | ATE348814T1 (pt) |
AU (1) | AU2003228195B2 (pt) |
BR (1) | BR0311674A (pt) |
CA (1) | CA2487329C (pt) |
CY (1) | CY1107555T1 (pt) |
DE (1) | DE60310554T2 (pt) |
DK (1) | DK1511732T5 (pt) |
ES (1) | ES2278160T3 (pt) |
HR (1) | HRP20050028B1 (pt) |
IL (1) | IL165155A (pt) |
IS (1) | IS2975B (pt) |
ME (1) | ME00435B (pt) |
MX (1) | MXPA04012276A (pt) |
NO (1) | NO329162B1 (pt) |
NZ (1) | NZ536768A (pt) |
PL (1) | PL210259B1 (pt) |
PT (1) | PT1511732E (pt) |
RS (1) | RS51021B (pt) |
RU (1) | RU2291861C2 (pt) |
SE (1) | SE0201778D0 (pt) |
SI (1) | SI1511732T1 (pt) |
UA (1) | UA78310C2 (pt) |
WO (1) | WO2003106424A1 (pt) |
ZA (1) | ZA200409430B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
CN101291911B (zh) * | 2005-10-19 | 2014-08-13 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
MX2008015808A (es) | 2006-06-12 | 2009-02-17 | Teva Pharma | Preparaciones de laquinimod estable. |
JP2010511052A (ja) | 2006-11-28 | 2010-04-08 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネル調節因子としての1,4ジアミノ二環式レチガビンアナログ |
EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
JP2012502038A (ja) | 2008-09-03 | 2012-01-26 | テバ ファーマシューティカル インダストリーズ リミティド | 免疫機能の2−オキソ−1,2−ジヒドロ−キノリンモジュレーター |
US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
US8598203B2 (en) | 2009-07-30 | 2013-12-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of Crohn's disease with laquinimod |
PL2467372T3 (pl) | 2009-08-10 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
ES2558556T3 (es) | 2010-03-03 | 2016-02-05 | Teva Pharmaceutical Industries Ltd. | Tratamiento de nefritis lúpica usando laquinimod |
US8501766B2 (en) | 2010-03-03 | 2013-08-06 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
CA2804986A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
EA201390074A1 (ru) * | 2010-07-09 | 2013-06-28 | Тева Фармасьютикал Индастриз Лтд. | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения |
CA2802006C (en) * | 2010-07-09 | 2018-09-25 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
KR20150091077A (ko) | 2012-11-07 | 2015-08-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드의 아민염 |
US9233927B2 (en) * | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
MX2016013944A (es) | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. |
PL3041472T3 (pl) | 2014-09-23 | 2017-08-31 | Active Biotech Ab | Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego |
BR112017009854B1 (pt) | 2014-11-19 | 2022-08-23 | Active Biotech Ab | Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia |
US20230085883A1 (en) | 2020-03-03 | 2023-03-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
CN111732540B (zh) * | 2020-07-20 | 2020-11-13 | 湖南速博生物技术有限公司 | 一种罗喹美克的制备方法 |
JP2023535021A (ja) | 2020-07-23 | 2023-08-15 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 骨髄増殖性腫瘍における新規治療用標的としてのs100タンパク質 |
JP2024503372A (ja) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
WO2022248401A1 (en) | 2021-05-25 | 2022-12-01 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
US20240277693A1 (en) | 2021-07-02 | 2024-08-22 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2002
- 2002-06-12 SE SE0201778A patent/SE0201778D0/xx unknown
-
2003
- 2003-05-14 PT PT03725956T patent/PT1511732E/pt unknown
- 2003-05-14 RU RU2005100054/04A patent/RU2291861C2/ru not_active IP Right Cessation
- 2003-05-14 NZ NZ536768A patent/NZ536768A/en not_active IP Right Cessation
- 2003-05-14 AT AT03725956T patent/ATE348814T1/de active
- 2003-05-14 JP JP2004513257A patent/JP4584709B2/ja not_active Expired - Lifetime
- 2003-05-14 DK DK03725956T patent/DK1511732T5/da active
- 2003-05-14 AU AU2003228195A patent/AU2003228195B2/en not_active Expired
- 2003-05-14 ME MEP-2008-656A patent/ME00435B/me unknown
- 2003-05-14 PL PL373817A patent/PL210259B1/pl unknown
- 2003-05-14 RS YUP-1076/04A patent/RS51021B/sr unknown
- 2003-05-14 CN CNB038135310A patent/CN100418950C/zh not_active Expired - Lifetime
- 2003-05-14 EP EP03725956A patent/EP1511732B9/en not_active Expired - Lifetime
- 2003-05-14 SI SI200330688T patent/SI1511732T1/sl unknown
- 2003-05-14 KR KR1020047020088A patent/KR100979216B1/ko active IP Right Grant
- 2003-05-14 UA UA20041109639A patent/UA78310C2/xx unknown
- 2003-05-14 WO PCT/SE2003/000780 patent/WO2003106424A1/en active IP Right Grant
- 2003-05-14 CA CA2487329A patent/CA2487329C/en not_active Expired - Lifetime
- 2003-05-14 MX MXPA04012276A patent/MXPA04012276A/es active IP Right Grant
- 2003-05-14 DE DE60310554T patent/DE60310554T2/de not_active Expired - Lifetime
- 2003-05-14 BR BRPI0311674-3A patent/BR0311674A/pt not_active Application Discontinuation
- 2003-05-14 ES ES03725956T patent/ES2278160T3/es not_active Expired - Lifetime
-
2004
- 2004-11-11 IL IL165155A patent/IL165155A/en active IP Right Grant
- 2004-11-23 ZA ZA200409430A patent/ZA200409430B/xx unknown
- 2004-11-24 IS IS7550A patent/IS2975B/is unknown
- 2004-12-29 NO NO20045703A patent/NO329162B1/no not_active IP Right Cessation
-
2005
- 2005-01-11 HR HRP20050028AA patent/HRP20050028B1/hr not_active IP Right Cessation
-
2007
- 2007-03-01 CY CY20071100295T patent/CY1107555T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050028B1 (hr) | Postupak za proizvodnju derivata kinolina | |
NO20055099L (no) | Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner | |
HUP0401647A2 (hu) | Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk | |
CA2446944A1 (en) | Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use | |
HUP0301699A2 (hu) | Imidazolil-anilin-származékok előállítása anilinek és azolok racionális ligandum-gyorsított Ullmann-kapcsolásával | |
DK1601653T3 (da) | Fremgangsmåde til fremstilling af substituerede nikotinsyreestre | |
MY141020A (en) | Novel pparalpha and ppargamma agonists | |
TW200720234A (en) | Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them | |
NO20055924L (no) | Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater | |
ES2161863T3 (es) | Procedimiento de produccion de inhibidores de proteasa de vih. | |
NO20031046D0 (no) | Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse | |
AU5209600A (en) | Orally active androgens | |
WO2003014094A3 (de) | Heterocyclylarylsulfonamide | |
WO2001083423A3 (en) | 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof | |
HUP0202335A2 (hu) | Eljárás optikailag aktív, vinil-szubsztituált ciklopropánkarbonsavak racemizálására | |
TW200621807A (en) | Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound | |
ES2184633A1 (es) | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida. | |
HUP0202296A2 (hu) | Eljárás szubsztituált benzizotiazolszármazékok előállítására | |
NO20044045L (no) | Ny fremgangsmate | |
TH72657A (th) | สารประกอบ |